Sign in

    Qian Wang

    Managing Director and Senior Analyst at Barclays

    Qian Wang is a Managing Director and Senior Analyst at Barclays, specializing in coverage of the China macroeconomics and Asian financial markets. She provides influential research and market insights for major companies in the region, including Alibaba, Tencent, and JD.com, and has earned recognition for her accurate forecasts and robust investment recommendations, with performance metrics including a success rate above 65% on TipRanks and consistently positive annualized returns for clients. Wang began her career in the early 2000s at the IMF before joining Barclays in 2011, after holding senior positions at Credit Suisse and Bank of America Merrill Lynch. She holds a PhD in Economics and maintains professional credentials with FINRA and securities licenses, frequently cited in financial media for her expertise.

    Qian Wang's questions to REGENXBIO (RGNX) leadership

    Qian Wang's questions to REGENXBIO (RGNX) leadership • Q1 2025

    Question

    Qian Wang from Barclays asked about potential FDA safety requirement changes for DMD gene therapies following a competitor's safety event, the impact on RGX-202's trial enrollment, and whether the new CBER Director might alter the accelerated approval path.

    Answer

    President and CEO Curran Simpson saw no signs of change to the accelerated approval path and noted their enrollment is on track. He highlighted RGX-202's differentiated safety profile and innovative immune suppression regimen. Chief Medical Officer Dr. Steve Pakola added that the competitor event brightens the spotlight on safety, which reinforces the value of their differentiated approach and gives the community comfort.

    Ask Fintool Equity Research AI